A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803
      QxMD      Google Scholar   
Citation:
Oncologist vol 22 (1) 107-114
Year:
2017
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Meta-Analysis
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
Yes
Book Volume:
6
Parents:
752  
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U24CA196171, U10 CA031946, U10 CA033601, U10 CA180821, P30 CA023108, U10 CA180882, U24 CA196171, T32 DK007754  
Corr. Author:
 
Authors:
                             
Networks:
CA011, LAPS-CT018, LAPS-MA036, LAPS-NH012, LAPS-NY016, LAPS-OH007   
Study
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-89803, CALGB-9581
Phases:
3
Keywords:
Colon cancer, Biomarkers, Adjuvant therapy, Thymidylate synthase, Microsatellite instability, Mismatch repair deficiency